191 completed, 64 terminated, 54 unknown, 47 recruiting. 200 Phase 2, 172 Phase 1, 38 Not applicable, 20 Phase 3, 19 Early Phase 1.
Follow Glioblastoma Multiforme: new trials by email Literature Review of Glioblastoma Multiforme trials Research Report on Glioblastoma Multiforme
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NG101m Adjuvant Therapy in Glioblastoma Patients Intensity-modulated radiation therapy, Temozolomide, NG101m - Glioblastoma Multiforme | Phase 1 / Phase 2 | Not yet recruiting | NeuGATE Theranostics | 52 | 2027-01-01 | 2025-10-21 |
| Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform Temozolomide, Disulfiram, Copper - Glioblastoma Multiforme | Phase 2 | Not yet recruiting | Olympion Medical Center | 32 | 2027-01-01 | 2025-05-25 |
| Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma LMP744, Conventional Surgery or Biopsy - Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 1 / Phase 2 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 40 | 2026-07-15 | 2026-10-16 |
| Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status) S-Gboxin - Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Suspended | Petrov, Andrey | 10 | 2026-05-20 | 2026-06-03 |
| Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients Normal diet, Cysteine/methionine deprivation (CMD) diet for 2 days, Cysteine/methionine deprivation (CMD) diet for 4 days - Glioblastoma Multiforme, Recurrent Glioma | Not applicable | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2026-05-01 | 2026-04-28 | |
| Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO] MRI & PET fusion, MRI+T1C - Glioblastoma Multiforme | Not applicable | Recruiting | Copernicus Memorial Hospital | 189 | 2025-12-08 | 2026-04-17 |
| Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma Ruxolitinib, Temozolomide, Radiation Therapy - Glioblastoma, Brain Cancer | Phase 2 | Recruiting | Baptist Health South Florida | 190 | 2025-12-03 | 2026-10-02 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma Biological G207 - Neoplasms, High Grade Glioma | Phase 2 | Withdrawn | Pediatric Brain Tumor Consortium | 2025-09-01 | 2026-02-10 | |
| Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2 - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Early Phase 1 | Recruiting | Nationwide Children's Hospital | 15 | 2025-08-03 | 2026-06-29 |
| Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma IA Carboplatin + IA Caelyx, IA Carboplatin + IA Etoposide Phosphate - Glioblastoma Multiforme, Relapse | Phase 2 | Recruiting | Université de Sherbrooke | 120 | 2025-08-01 | 2025-08-07 |
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age SIACI of cetuximab and bevacizumab - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 / Phase 2 | Recruiting | University of Miami | 20 | 2025-06-19 | 2025-12-08 |
| Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-time Escalation Pilot Trial Oncomagnetic device - Glioblastoma Multiforme | Not applicable | Recruiting | BioTex, Inc. | 30 | 2025-02-17 | 2026-06-02 |
| Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue Specimen Collection - Glioblastoma, Glioblastoma Multiforme | Recruiting | Baptist Health South Florida | 120 | 2024-12-11 | 2026-02-04 | |
| Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma ICT-107, Placebo - Glioblastoma Multiforme | Phase 3 | Suspended | Precision Life Sciences Group | 234 | 2024-12-01 | 2024-04-03 |
| The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM Haloperidol Tablets, Temozolomide - Glioblastoma Multiforme | Phase 2 | Not yet recruiting | Southern Medical University, China | 200 | 2024-12-01 | 2024-01-23 |
| A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound - Glioblastoma Multiforme, Glioblastoma | Phase 3 | Recruiting | NaviFUS Corporation | 32 | 2024-11-08 | 2026-04-09 |
| Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) NaviFUS System, Lumason, Bevacizumab - Glioblastoma Multiforme, Glioblastoma | Phase 1 / Phase 2 | Suspended | NaviFUS Corporation | 10 | 2024-10-22 | 2026-09-09 |
| Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma TS-2021 - Glioblastoma Multiforme, Glioma, Malignant | Phase 1 | Unknown | Beijing Neurosurgical Institute | 30 | 2024-08-29 | 2024-10-31 |
| Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant Ribociclib, Everolimus, Temozolomide (TMZ) - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Recruiting | Nationwide Children's Hospital | 120 | 2024-08-22 | 2026-05-29 |
Showing 20 of 427. Sign in to see all of them.
Glioblastoma (427) · Glioma (125) · Brain Neoplasms (124) · Astrocytoma (81) · Neoplasms (35) · Gliosarcoma (33) · Oligodendroglioma (31) · Recurrence (20) · Central Nervous System Neoplasms (11) · Diffuse Intrinsic Pontine Glioma (9) · Ependymoma (9) · Carcinoma, Non-Small-Cell Lung (8) · Melanoma (8) · Pancreatic Neoplasms (7) · Breast Neoplasms (6)
Neoplasms, Germ Cell and Embryonal (426) · Neoplasms, Glandular and Epithelial (426) · Neoplasms by Histologic Type (425) · Neoplasms, Neuroepithelial (425) · Neuroectodermal Tumors (425) · Neoplasms, Nerve Tissue (421) · Neoplasms (392) · Astrocytoma (346) · Glioma (302) · Neoplasms by Site (149) · Nervous System Diseases (133) · Nervous System Neoplasms (130) · Brain Diseases (126) · Central Nervous System Diseases (125) · Central Nervous System Neoplasms (122)
Temozolomide (99) · Bevacizumab (51) · Radiotherapy (41) · Surgical Procedures, Operative (13) · Radiation (11) · Carmustine (9) · Irinotecan (9) · Lomustine (9) · Carboplatin (6) · IL13-PE38 (6) · Magnetic Resonance Spectroscopy (6) · Radiosurgery (6) · Cyclophosphamide (5) · Drug Therapy (5) · Flucytosine (5)
National Cancer Institute (NCI) (13) · Northwell Health (11) · M.D. Anderson Cancer Center (9) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (7) · INSYS Therapeutics Inc (6) · Washington University School of Medicine (6) · Duke University (5) · Hoffmann-La Roche (5) · Novartis Pharmaceuticals (5) · University of Florida (5) · AbbVie (4) · Jasper Gerritsen (4) · Nader Sanai (4) · NaviFUS Corporation (4) · Pediatric Brain Tumor Consortium (4)
United States (268) · Canada (29) · Germany (28) · Netherlands (17) · Australia (16) · United Kingdom (15) · France (14) · Spain (14) · China (13) · Italy (12) · Taiwan (12) · Switzerland (11) · Israel (10) · Austria (8) · Belgium (7)
John Boockvar, MD (9) · Nader Sanai, MD (5) · Teri N Kreisl, M.D. (4) · Asha Das, MD (3) · Donna Morgan Murray, PhD (3) · E. Antonio Chiocca, MD, PhD (3) · Jasper Gerritsen, MD PhD (3) · John M. Buatti, MD (3) · Katherine B Peters, MD, PhD (3) · Katherine E Warren, M.D. (3) · Lawrence Kleinberg, MD (3) · Maryam Fouladi, MD (3)
PMID 16520474, PMID 15727424, PMID 15809479, PMID 16648043, PMID 16877732, PMID 17429084, PMID 18981465, PMID 19075262, PMID 19534336, PMID 19760366, PMID 20564147, PMID 20615924, PMID 20729242, PMID 21499132, PMID 21715171, PMID 21792866, PMID 21844505, PMID 22284691, PMID 22483738, PMID 22847020, PMID 22931705, PMID 23388562, PMID 23404447, PMID 23545055, PMID 23560574, PMID 23566417, PMID 23844725, PMID 23891088, PMID 24026531, PMID 24111225, PMID 24256396, PMID 24311637, PMID 24344045, PMID 24947313, PMID 25239666, PMID 25915780, PMID 25944802, PMID 26025933, PMID 26106073, PMID 26392096, PMID 26541586, PMID 26670971, PMID 26843484, PMID 26951379, PMID 26976423, PMID 27252174, PMID 27580889, PMID 27744512, PMID 27799506, PMID 28079702
UM1CA081457 (5), 2014 (3), 2009 (2), 2016 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1), P30CA086862 (1), P50CA097257 (1), P50CA221747 (1), R01CA125244 (1), R01CA175517 (1), R01CA203861 (1), R01CA276174 (1)